Measured Wealth Private Client Group’s First Trust Nasdaq Pharmaceuticals ETF FTXH Stock Holding History

Measured Wealth Private Client Group’s Portfolio FTXH Stock Details FTXH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-2,000	Closed	-$47K	–	320
2018 Q3	$47K	Buy	+2,000	New	+$46.4K	0.03%	368

Other funds holding FTXH

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

SMFS

Squar Milner Financial Services Irvine, California $176M AUM 10.56% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Claro Advisors Boston, Massachusetts $830M AUM 21.8% 1-Year Est. Return

Measured Wealth Private Client Group's FTXH Position: Q4 2018 in Review

Measured Wealth Private Client Group sold out of First Trust Nasdaq Pharmaceuticals ETF (FTXH) in Q4 2018, closing a stake of 2,000 shares — an estimated $47K sold.

Measured Wealth Private Client Group first reported a position in FTXH in Q3 2018 and held it in 1 quarter. The position peaked at $47K in Q3 2018. 6 funds tracked by Wall St. Rank hold FTXH as of Q4 2018.

Measured Wealth Private Client Group reported no remaining First Trust Nasdaq Pharmaceuticals ETF position as of Q4 2018 after selling out during the quarter.
Measured Wealth Private Client Group sold 2,000 First Trust Nasdaq Pharmaceuticals ETF shares in Q4 2018, an estimated $47K.
Measured Wealth Private Client Group first reported a position in First Trust Nasdaq Pharmaceuticals ETF in Q3 2018 and held it in 1 quarter.
Measured Wealth Private Client Group's First Trust Nasdaq Pharmaceuticals ETF position peaked at $47K in Q3 2018.
6 funds tracked by Wall St. Rank held First Trust Nasdaq Pharmaceuticals ETF as of Q4 2018.

Based on Measured Wealth Private Client Group's 13F filing for Q4 2018, filed 7 Feb 2019.